Divi’s Laboratories’ (Divi’s) Q3FY23 performance was well below our estimates. Consolidated revenues fell 7.9% QoQ to Rs17.1bn (I-Sec: Rs20.5bn), EBITDA margin slipped to its lowest-ever at 23.9% (-2,010bps YoY, -960bpsQoQ)